Journal
BIOLOGY-BASEL
Volume 10, Issue 6, Pages -Publisher
MDPI
DOI: 10.3390/biology10060455
Keywords
metachronous gastric cancer; endoscopic resection; antibiotics; probiotics; gut microbiome
Categories
Funding
- KAKENHI [20K08375, 17H05081]
- JSPS
- Inoue Science Research Award
- Takeda Science Foundation Visionary Research Grant
- Uehara Memorial Foundation
- Naito Foundation
- Daiwa-Shoken health foundation
- Waksman Foundation of Japan
- Koyanagi Foundation
- Research Foundation for Pharmaceutical Sciences
- Yakult Bio-Science Foundation
- Tokyo Biochemical Research Foundation
- The NOVARTIS Foundation (Japan) for the Promotion of Science
- SGH foundation
- Daiichi Sankyo Foundation of Life Science
- AMED (PRIME)
- AMED (P-CREATE)
- Grants-in-Aid for Scientific Research [17H05081, 20K08375] Funding Source: KAKEN
Ask authors/readers for more resources
Helicobacter pylori is a major cause of gastric cancer and its eradication can reduce the incidence of gastric cancer after endoscopic resection. However, the risk of metachronous gastric cancer remains high. The use of antibiotics and probiotic drugs was found to be associated with a decreased risk of metachronous gastric cancer, suggesting a potential link between the gut microbiome and the development of this type of cancer.
Simple Summary Helicobacter pylori is the most important cause of gastric cancer, and its eradication reduces the incidence of gastric cancer after endoscopic resection. However, incidence of metachronous gastric cancer is still high. More studies are needed to identify other chemopreventive drugs that may reduce the incidence of this disease. In this study, we focused on the alteration of the intragastric microbiome and examined the association between the use of antibiotics and probiotic drugs and risk of metachronous gastric cancer. Our findings suggest that the gut microbiome is associated with metachronous gastric cancer development. Metachronous gastric cancer often occurs after endoscopic resection. Appropriate management, including chemoprevention, is required after the procedure. This study was performed to evaluate the association between medication use and the incidence of metachronous gastric cancer after endoscopic resection. This multicenter retrospective cohort study was conducted with data from nine hospital databases on patients who underwent endoscopic resection for gastric cancer between 2014 and 2019. The primary outcome was the incidence of metachronous gastric cancer. We evaluated the associations of metachronous gastric cancer occurrence with medication use and clinical factors. Hazard ratios were adjusted by age and Charlson comorbidity index scores, with and without consideration of sex, smoking status, and receipt of Helicobacter pylori eradication therapy during the study period. During a mean follow-up period of 2.55 years, 10.39% (140/1347) of all patients developed metachronous gastric cancer. The use of antibiotics other than those used for H. pylori eradication was associated with a lower incidence of metachronous gastric cancer than was non-use (adjusted hazard ratio (aHR) 0.56, 95% confidence interval (CI) 0.38-0.85, p = 0.006). Probiotic drug use was also associated with a lower incidence of metachronous gastric cancer compared with non-use (aHR 0.29, 95% CI 0.091-0.91, p = 0.034). In conclusion, the use of antibiotics and probiotic drugs was associated with a decreased risk of metachronous gastric cancer. These findings suggest that the gut microbiome is associated with metachronous gastric cancer development.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available